{
  "paper_id": "PMC10551887",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551887/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Figure 1.",
      "caption": "Cumulative rates of intracranial bleeding within the first 3 months in patients with brain cancer, cancer in other sites, or no cancer.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5157/10551887/c7e98e0dafc6/gr1.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5157/10551887/c7e98e0dafc6/gr1.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5157/10551887/c7e98e0dafc6/gr1.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5157/10551887/c7e98e0dafc6/gr1.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5157/10551887/c7e98e0dafc6/gr1.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10551887/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5157/10551887/c7e98e0dafc6/gr1.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Figure 2.",
      "caption": "Cumulative rates of fatal pulmonary embolism and fatal bleeding within the first 3 months in patients with brain cancer and in those with other cancers. PE, pulmonary embolism.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5157/10551887/1c549122cc90/gr2.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5157/10551887/1c549122cc90/gr2.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5157/10551887/1c549122cc90/gr2.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5157/10551887/1c549122cc90/gr2.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5157/10551887/1c549122cc90/gr2.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10551887/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5157/10551887/1c549122cc90/gr2.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "Figure 3.",
      "caption": "Cumulative rates of intracranial bleeding within the first 3 months in patients with glioblastoma vs other brain cancers.",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5157/10551887/29c1cb2f4559/gr3.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5157/10551887/29c1cb2f4559/gr3.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5157/10551887/29c1cb2f4559/gr3.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5157/10551887/29c1cb2f4559/gr3.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "fig3",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5157/10551887/29c1cb2f4559/gr3.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC10551887/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5157/10551887/29c1cb2f4559/gr3.jpg"
    }
  },
  "claims": [
    {
      "sentence": "Cumulative rates of ICH continued to increase during anticoagulation in patients with brain cancer (from 0.33% at 10 days to 3.16% at 90 days from the index VTE), whereas the increase was less pronounced in patients with nonbrain cancer or without cancer (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "At completing the risk analysis, brain cancer was the strongest predictor of ICH (subdistribution HR, 13.9; 95% CI, 8.05-24.1) compared with nonbrain cancer (subdistribution HR, 1.60; 95% CI, 1.15-2.21) and without cancer (reference) (Table 4 and Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In addition, in patients with active brain cancer, death due to bleeding continued to increase during follow-up, whereas rates of death due to VTE (fatal PE) were higher in the early phases after VTE diagnosis and then reached a plateau (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "At completing the multivariable risk analysis, patients with brain cancer and nonbrain cancer had a higher risk of recurrent VTE (subdistribution HR, 3.23; 95% CI, 2.13-4.86 and subdistribution HR, 2.97; 95% CI, 2.64-3.34, respectively) than patients without cancer (Table 4 and Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rates of ICH, fatal ICH, and recurrent VTE were numerically (not significantly) higher in patients with glioblastoma than those with other malignant brain tumors (Table 5 and Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Cumulative rates of ICH continued to increase during anticoagulation in patients with brain cancer (from 0.33% at 10 days to 3.16% at 90 days from the index VTE), whereas the increase was less pronounced in patients with nonbrain cancer or without cancer (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "At completing the risk analysis, brain cancer was the strongest predictor of ICH (subdistribution HR, 13.9; 95% CI, 8.05-24.1) compared with nonbrain cancer (subdistribution HR, 1.60; 95% CI, 1.15-2.21) and without cancer (reference) (Table 4 and Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In addition, in patients with active brain cancer, death due to bleeding continued to increase during follow-up, whereas rates of death due to VTE (fatal PE) were higher in the early phases after VTE diagnosis and then reached a plateau (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "At completing the multivariable risk analysis, patients with brain cancer and nonbrain cancer had a higher risk of recurrent VTE (subdistribution HR, 3.23; 95% CI, 2.13-4.86 and subdistribution HR, 2.97; 95% CI, 2.64-3.34, respectively) than patients without cancer (Table 4 and Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rates of ICH, fatal ICH, and recurrent VTE were numerically (not significantly) higher in patients with glioblastoma than those with other malignant brain tumors (Table 5 and Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Cumulative rates of ICH continued to increase during anticoagulation in patients with brain cancer (from 0.33% at 10 days to 3.16% at 90 days from the index VTE), whereas the increase was less pronounced in patients with nonbrain cancer or without cancer (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "At completing the risk analysis, brain cancer was the strongest predictor of ICH (subdistribution HR, 13.9; 95% CI, 8.05-24.1) compared with nonbrain cancer (subdistribution HR, 1.60; 95% CI, 1.15-2.21) and without cancer (reference) (Table 4 and Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In addition, in patients with active brain cancer, death due to bleeding continued to increase during follow-up, whereas rates of death due to VTE (fatal PE) were higher in the early phases after VTE diagnosis and then reached a plateau (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "At completing the multivariable risk analysis, patients with brain cancer and nonbrain cancer had a higher risk of recurrent VTE (subdistribution HR, 3.23; 95% CI, 2.13-4.86 and subdistribution HR, 2.97; 95% CI, 2.64-3.34, respectively) than patients without cancer (Table 4 and Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rates of ICH, fatal ICH, and recurrent VTE were numerically (not significantly) higher in patients with glioblastoma than those with other malignant brain tumors (Table 5 and Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Cumulative rates of ICH continued to increase during anticoagulation in patients with brain cancer (from 0.33% at 10 days to 3.16% at 90 days from the index VTE), whereas the increase was less pronounced in patients with nonbrain cancer or without cancer (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "At completing the risk analysis, brain cancer was the strongest predictor of ICH (subdistribution HR, 13.9; 95% CI, 8.05-24.1) compared with nonbrain cancer (subdistribution HR, 1.60; 95% CI, 1.15-2.21) and without cancer (reference) (Table 4 and Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In addition, in patients with active brain cancer, death due to bleeding continued to increase during follow-up, whereas rates of death due to VTE (fatal PE) were higher in the early phases after VTE diagnosis and then reached a plateau (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "At completing the multivariable risk analysis, patients with brain cancer and nonbrain cancer had a higher risk of recurrent VTE (subdistribution HR, 3.23; 95% CI, 2.13-4.86 and subdistribution HR, 2.97; 95% CI, 2.64-3.34, respectively) than patients without cancer (Table 4 and Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rates of ICH, fatal ICH, and recurrent VTE were numerically (not significantly) higher in patients with glioblastoma than those with other malignant brain tumors (Table 5 and Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Cumulative rates of ICH continued to increase during anticoagulation in patients with brain cancer (from 0.33% at 10 days to 3.16% at 90 days from the index VTE), whereas the increase was less pronounced in patients with nonbrain cancer or without cancer (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "At completing the risk analysis, brain cancer was the strongest predictor of ICH (subdistribution HR, 13.9; 95% CI, 8.05-24.1) compared with nonbrain cancer (subdistribution HR, 1.60; 95% CI, 1.15-2.21) and without cancer (reference) (Table 4 and Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In addition, in patients with active brain cancer, death due to bleeding continued to increase during follow-up, whereas rates of death due to VTE (fatal PE) were higher in the early phases after VTE diagnosis and then reached a plateau (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "At completing the multivariable risk analysis, patients with brain cancer and nonbrain cancer had a higher risk of recurrent VTE (subdistribution HR, 3.23; 95% CI, 2.13-4.86 and subdistribution HR, 2.97; 95% CI, 2.64-3.34, respectively) than patients without cancer (Table 4 and Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rates of ICH, fatal ICH, and recurrent VTE were numerically (not significantly) higher in patients with glioblastoma than those with other malignant brain tumors (Table 5 and Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Cumulative rates of ICH continued to increase during anticoagulation in patients with brain cancer (from 0.33% at 10 days to 3.16% at 90 days from the index VTE), whereas the increase was less pronounced in patients with nonbrain cancer or without cancer (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "At completing the risk analysis, brain cancer was the strongest predictor of ICH (subdistribution HR, 13.9; 95% CI, 8.05-24.1) compared with nonbrain cancer (subdistribution HR, 1.60; 95% CI, 1.15-2.21) and without cancer (reference) (Table 4 and Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In addition, in patients with active brain cancer, death due to bleeding continued to increase during follow-up, whereas rates of death due to VTE (fatal PE) were higher in the early phases after VTE diagnosis and then reached a plateau (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "At completing the multivariable risk analysis, patients with brain cancer and nonbrain cancer had a higher risk of recurrent VTE (subdistribution HR, 3.23; 95% CI, 2.13-4.86 and subdistribution HR, 2.97; 95% CI, 2.64-3.34, respectively) than patients without cancer (Table 4 and Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rates of ICH, fatal ICH, and recurrent VTE were numerically (not significantly) higher in patients with glioblastoma than those with other malignant brain tumors (Table 5 and Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Cumulative rates of ICH continued to increase during anticoagulation in patients with brain cancer (from 0.33% at 10 days to 3.16% at 90 days from the index VTE), whereas the increase was less pronounced in patients with nonbrain cancer or without cancer (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "At completing the risk analysis, brain cancer was the strongest predictor of ICH (subdistribution HR, 13.9; 95% CI, 8.05-24.1) compared with nonbrain cancer (subdistribution HR, 1.60; 95% CI, 1.15-2.21) and without cancer (reference) (Table 4 and Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In addition, in patients with active brain cancer, death due to bleeding continued to increase during follow-up, whereas rates of death due to VTE (fatal PE) were higher in the early phases after VTE diagnosis and then reached a plateau (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "At completing the multivariable risk analysis, patients with brain cancer and nonbrain cancer had a higher risk of recurrent VTE (subdistribution HR, 3.23; 95% CI, 2.13-4.86 and subdistribution HR, 2.97; 95% CI, 2.64-3.34, respectively) than patients without cancer (Table 4 and Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rates of ICH, fatal ICH, and recurrent VTE were numerically (not significantly) higher in patients with glioblastoma than those with other malignant brain tumors (Table 5 and Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Cumulative rates of ICH continued to increase during anticoagulation in patients with brain cancer (from 0.33% at 10 days to 3.16% at 90 days from the index VTE), whereas the increase was less pronounced in patients with nonbrain cancer or without cancer (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "At completing the risk analysis, brain cancer was the strongest predictor of ICH (subdistribution HR, 13.9; 95% CI, 8.05-24.1) compared with nonbrain cancer (subdistribution HR, 1.60; 95% CI, 1.15-2.21) and without cancer (reference) (Table 4 and Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In addition, in patients with active brain cancer, death due to bleeding continued to increase during follow-up, whereas rates of death due to VTE (fatal PE) were higher in the early phases after VTE diagnosis and then reached a plateau (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "At completing the multivariable risk analysis, patients with brain cancer and nonbrain cancer had a higher risk of recurrent VTE (subdistribution HR, 3.23; 95% CI, 2.13-4.86 and subdistribution HR, 2.97; 95% CI, 2.64-3.34, respectively) than patients without cancer (Table 4 and Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rates of ICH, fatal ICH, and recurrent VTE were numerically (not significantly) higher in patients with glioblastoma than those with other malignant brain tumors (Table 5 and Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Cumulative rates of ICH continued to increase during anticoagulation in patients with brain cancer (from 0.33% at 10 days to 3.16% at 90 days from the index VTE), whereas the increase was less pronounced in patients with nonbrain cancer or without cancer (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "At completing the risk analysis, brain cancer was the strongest predictor of ICH (subdistribution HR, 13.9; 95% CI, 8.05-24.1) compared with nonbrain cancer (subdistribution HR, 1.60; 95% CI, 1.15-2.21) and without cancer (reference) (Table 4 and Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In addition, in patients with active brain cancer, death due to bleeding continued to increase during follow-up, whereas rates of death due to VTE (fatal PE) were higher in the early phases after VTE diagnosis and then reached a plateau (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "At completing the multivariable risk analysis, patients with brain cancer and nonbrain cancer had a higher risk of recurrent VTE (subdistribution HR, 3.23; 95% CI, 2.13-4.86 and subdistribution HR, 2.97; 95% CI, 2.64-3.34, respectively) than patients without cancer (Table 4 and Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rates of ICH, fatal ICH, and recurrent VTE were numerically (not significantly) higher in patients with glioblastoma than those with other malignant brain tumors (Table 5 and Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Cumulative rates of ICH continued to increase during anticoagulation in patients with brain cancer (from 0.33% at 10 days to 3.16% at 90 days from the index VTE), whereas the increase was less pronounced in patients with nonbrain cancer or without cancer (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "At completing the risk analysis, brain cancer was the strongest predictor of ICH (subdistribution HR, 13.9; 95% CI, 8.05-24.1) compared with nonbrain cancer (subdistribution HR, 1.60; 95% CI, 1.15-2.21) and without cancer (reference) (Table 4 and Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In addition, in patients with active brain cancer, death due to bleeding continued to increase during follow-up, whereas rates of death due to VTE (fatal PE) were higher in the early phases after VTE diagnosis and then reached a plateau (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "At completing the multivariable risk analysis, patients with brain cancer and nonbrain cancer had a higher risk of recurrent VTE (subdistribution HR, 3.23; 95% CI, 2.13-4.86 and subdistribution HR, 2.97; 95% CI, 2.64-3.34, respectively) than patients without cancer (Table 4 and Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Cumulative rates of ICH continued to increase during anticoagulation in patients with brain cancer (from 0.33% at 10 days to 3.16% at 90 days from the index VTE), whereas the increase was less pronounced in patients with nonbrain cancer or without cancer (Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "At completing the risk analysis, brain cancer was the strongest predictor of ICH (subdistribution HR, 13.9; 95% CI, 8.05-24.1) compared with nonbrain cancer (subdistribution HR, 1.60; 95% CI, 1.15-2.21) and without cancer (reference) (Table 4 and Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In addition, in patients with active brain cancer, death due to bleeding continued to increase during follow-up, whereas rates of death due to VTE (fatal PE) were higher in the early phases after VTE diagnosis and then reached a plateau (Figure 2).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "At completing the multivariable risk analysis, patients with brain cancer and nonbrain cancer had a higher risk of recurrent VTE (subdistribution HR, 3.23; 95% CI, 2.13-4.86 and subdistribution HR, 2.97; 95% CI, 2.64-3.34, respectively) than patients without cancer (Table 4 and Figure 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Rates of ICH, fatal ICH, and recurrent VTE were numerically (not significantly) higher in patients with glioblastoma than those with other malignant brain tumors (Table 5 and Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Rates of ICH, fatal ICH, and recurrent VTE were numerically (not significantly) higher in patients with glioblastoma than those with other malignant brain tumors (Table 5 and Figure 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 3,
    "claims_count": 55,
    "images_downloaded": 3,
    "tables_filtered": 16
  }
}